# Optimizing [18F]FAPI-74 PET/CT imaging: insights from Early-phase tumor uptake and tissue contrast

**Authors:** Yuki Hoda, Keiji Shimizu, Hiroyuki Nishida, Yasuhiko Ikari, Go Akamatsu, Keiichi Matsumoto, Michio Senda, Tomohiko Yamane

PMC · DOI: 10.1186/s13550-025-01356-x · EJNMMI Research · 2025-12-04

## TL;DR

This study explores early-phase [18F]FAPI-74 PET/CT imaging in cancer patients, finding that it provides useful diagnostic contrast despite low background uptake.

## Contribution

The study provides new insights into the timing and contrast of [18F]FAPI-74 PET/CT imaging for tumor detection.

## Key findings

- Tumor SUVmax values remained stable over time, while tumor-to-blood ratios increased significantly.
- Early-phase imaging showed low physiological uptake in the biliary system and sufficient diagnostic contrast.
- Tumor-to-blood ratios were highest at 60 minutes post-administration across various lesion types.

## Abstract

Fibroblast activation protein inhibitor (FAPI) is a novel PET tracer that targets various malignant tumors. Although some studies have demonstrated that 68Ga-labeled FAPI PET provides diagnostic images shortly after injection, reports on early-phase imaging using [18F]FAPI-74 are limited. This study evaluated the diagnostic potential of early-phase [18F]FAPI-74 PET/CT imaging.

The cohort comprised 32 patients who underwent whole-body [18F]FAPI-74 PET/CT at three time points: 10, 30, and 60 min after administration. The uptake of [18F]FAPI-74 in normal organs and tumors at each time point was evaluated and compared using standardized uptake value (SUV). The contrast between tumor and background uptake was assessed using tumor-to-blood ratios (TBRs), calculated as the ratio of tumor SUVmax to blood pool SUVmean.

The uptake of [18F]FAPI-74 in most organs gradually decreased, except in the mammary gland and nipple. Moreover, uptake due to the excretion increased over time in the gallbladder, and bile duct. Among the 72 lesions identified across patients, the median SUVmax of the tumors remained relatively stable across the time points (5.00, 5.16, and 5.11 at 10, 30, and 60 min, respectively), while the median TBRs gradually increased (1.57, 2.24, and 2.94, respectively). Subgroup analysis revealed a similar pattern of increasing median TBRs in primary tumors (2.76, 3.72, and 4.04, respectively), lymph node metastases and peritoneal dissemination (1.67, 2.47, and 3.58, respectively), and lung metastases (0.99, 1.35, and 1.48, respectively).

TBRs were highest at 60 min after administration. However, early-phase imaging was considered useful because of its sufficient diagnostic contrast and low physiological uptake in the biliary system.

UMIN Clinical Trials Registry, UMIN000051687. Registered 22 July 2023, https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_his_list.cgi?recptno=R000058594.

## Linked entities

- **Chemicals:** [18F]FAPI-74 (PubChem CID 171390022)

## Full-text entities

- **Diseases:** tumor (MESH:D009369)
- **Chemicals:** [18F]FAPI-74 (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12796034/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12796034/full.md

---
Source: https://tomesphere.com/paper/PMC12796034